Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

Fig. 1

Efficacy evaluation of YY-20394 treatments in the dose escalation study of B-cell malignancies. a Overall efficacy chart of YY-20394. b Waterfall plot of overall tumor changes from baseline #indicates transient staging with ongoing treatment at the end of the study period. c PFS curve (days) in the 5 patient dosing groups. Note: CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; LPL, Lymphatic plasma cell lymphoma; MCL, mantle cell lymphoma; MZL marginal zone lymphoma; PD, progressive disease; PR, partial remission; SD, stable disease

Back to article page